Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease

Waters, 2013, Latest statistics on cardiovascular disease in Australia, Clin Exp Pharmacol Physiol, 40, 347, 10.1111/1440-1681.12079 Dabelea, 2003, Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study, Diabetes, 52, 2833, 10.2337/diabetes.52.11.2833 Qasim, 2011, Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women, Int J Cardiol, 150, 17, 10.1016/j.ijcard.2010.02.021 Bierhaus, 2005, Advanced glycation end product receptor-mediated cellular dysfunction, Ann N Y Acad Sci, 1043, 676, 10.1196/annals.1333.077 Peppa, 2003, Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice, Diabetes, 52, 1441, 10.2337/diabetes.52.6.1441 Schalkwijk, 2005, Vascular complications in diabetes mellitus: the role of endothelial dysfunction, Clin Sci (Lond), 109, 143, 10.1042/CS20050025 Schram, 2005, Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study, Hypertension, 46, 232, 10.1161/01.HYP.0000164574.60279.ba Zong, 2010, Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction, J Biol Chem, 285, 23137, 10.1074/jbc.M110.133827 Nargund, 2012, Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation, Science, 337, 587, 10.1126/science.1223560 Nin, 2011, Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study, Diabetes Care, 34, 442, 10.2337/dc10-1087 Willemsen, 2012, The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction, Am Heart J, 164, 742, 10.1016/j.ahj.2012.07.027 Norman, 2009, Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study, J Vasc Surg, 50, 626, 10.1016/j.jvs.2009.05.058 Abi Khalil, 2012, Cause-specific mortality in diabetes: recent changes in trend mortality, Eur J Prev Cardiol, 19, 374, 10.1177/1741826711409324 Engelen, 2011, Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes, Eur J Endocrinol, 164, 371, 10.1530/EJE-10-0851 Liu, 2011, Advanced glycation end products accelerate ischemia/reperfusion injury through receptor of advanced end product/nitrative thioredoxin inactivation in cardiac microvascular endothelial cells, Antioxid Redox Signal, 15, 1769, 10.1089/ars.2010.3764 Xu, 2003, Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products, FASEB J, 17, 1289, 10.1096/fj.02-0490fje Kaneko, 2005, Aldose reductase and AGE–RAGE pathways: key players in myocardial ischemic injury, Ann N Y Acad Sci, 1043, 702, 10.1196/annals.1333.081 Ma, 2009, Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy, J Cell Mol Med, 13, 1751, 10.1111/j.1582-4934.2008.00547.x Palinski, 1995, Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits, Arterioscler Thromb Vasc Biol, 15, 571, 10.1161/01.ATV.15.5.571 Soro-Paavonen, 2008, Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes, Diabetes, 57, 2461, 10.2337/db07-1808 Cai, 2010, AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease, Am J Physiol Cell Physiol, 298, C624, 10.1152/ajpcell.00463.2009 Peppa, 2003, Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice, Diabetes, 52, 2805, 10.2337/diabetes.52.11.2805 Zheng, 2001, Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential AGE sequestration therapy for diabetic nephropathy?, Mol Med, 7, 737, 10.1007/BF03401963 Rabbani, 2011, Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes, Diabetes, 60, 1973, 10.2337/db11-0085 Ke, 2012, Tissue-specific splicing of an Ndufs6 gene-trap insertion generates a mitochondrial complex I deficiency-specific cardiomyopathy, Proc Natl Acad Sci U S A, 109, 6165, 10.1073/pnas.1113987109 Weidemann, 2012, The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms, Circulation, 125, 1626, 10.1161/CIRCULATIONAHA.111.059477 Kim, 2012, Various indications for a modified Atkins diet in intractable childhood epilepsy, Brain Dev, 34, 570, 10.1016/j.braindev.2011.09.013 Zieman, 2007, Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension, J Hypertens, 25, 577, 10.1097/HJH.0b013e328013e7dd Ramli, 2011, Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease, Cardiol J, 18, 352 Dal-Pizzol, 2012, Is there a role for high mobility group box 1 and the receptor for advanced glycation end products in the genesis of long-term cognitive impairment in sepsis survivors?, Mol Med, 18, 1357, 10.2119/molmed.2012.00317 Baumann, 2012, Role of advanced glycation end products in hypertension and cardiovascular risk: human studies, J Am Soc Hypertens, 6, 427, 10.1016/j.jash.2012.10.005 Baumann, 2009, Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML), Cardiovasc Diabetol, 8, p45, 10.1186/1475-2840-8-45 Tilton, 2002, Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF, Microsc Res Tech, 57, 390, 10.1002/jemt.10092 Semba, 2009, Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults, Am J Hypertens, 22, 74, 10.1038/ajh.2008.320 Bucciarelli, 2006, Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury, Circulation, 113, 1226, 10.1161/CIRCULATIONAHA.105.575993 Lapar, 2012, Acute hyperglycemic exacerbation of lung ischemia–reperfusion injury is mediated by receptor for advanced glycation end-products signaling, Am J Respir Cell Mol Biol, 46, 299, 10.1165/rcmb.2011-0247OC Tsoporis, 2010, S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction, Circ Res, 106, 93, 10.1161/CIRCRESAHA.109.195834 Kumagai, 2009, Glyoxalase I overexpression ameliorates renal ischemia–reperfusion injury in rats, Am J Physiol Renal Physiol, 296, F912, 10.1152/ajprenal.90575.2008 He, 2012, Risk factors for coronary artery calcium among patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study), Am J Cardiol, 110, 1735, 10.1016/j.amjcard.2012.07.044 Forbes, 2013, Mechanisms of diabetic complications, Physiol Rev, 93, 137, 10.1152/physrev.00045.2011 Forbes, 2013, Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease, Antioxid Redox Signal, 19, 331, 10.1089/ars.2012.4719 Tan, 2010, Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy, Am J Physiol Renal Physiol, 298, F763, 10.1152/ajprenal.00591.2009 Forbes, 2003, The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes, FASEB J, 17, 1762, 10.1096/fj.02-1102fje Thomas, 2005, Interactions between renin–angiotensin system and advanced glycation in the kidney, J Am Soc Nephrol, 16, 2976, 10.1681/ASN.2005010013 Coughlan, 2009, RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes, J Am Soc Nephrol, 20, 742, 10.1681/ASN.2008050514 Harrison, 2003, Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease, J Renin Angiotensin Aldosterone Syst, 4, 51, 10.3317/jraas.2003.014 Coughlan, 2007, Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?, Endocrinology, 148, 886, 10.1210/en.2006-1300 Piotrkowski, 2007, Mitochondrial function and nitric oxide metabolism are modified by enalapril treatment in rat kidney, Am J Physiol Regul Integr Comp Physiol, 292, R1494, 10.1152/ajpregu.00540.2006 Gallicchio, 2010, Advanced glycation end products inhibit Na+K+ ATPase in proximal tubule epithelial cells: role of cytosolic phospholipase A2alpha and phosphatidylinositol 4-phosphate 5-kinase gamma, Biochim Biophys Acta, 1803, 919, 10.1016/j.bbamcr.2010.04.009 Han, 2008, Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats, Diabetes, 57, 1723, 10.2337/db07-1472 Yamagishi, 2003, Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation, Drugs Exp Clin Res, 29, 75 Muscari, 1995, Association of serum C3 levels with the risk of myocardial infarction, Am J Med, 98, 357, 10.1016/S0002-9343(99)80314-3 Muscari, 1990, Involvement of the immune system in atherosclerosis, Cardiologia, 35, 977 Zhang, 2003, Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries, Circulation, 108, 472, 10.1161/01.CIR.0000080378.96063.23 Lewis, 2012, Pyridorin in type 2 diabetic nephropathy, J Am Soc Nephrol, 23, 131, 10.1681/ASN.2011030272 Alkhalaf, 2010, A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy, Diabetes Care, 33, 1598, 10.2337/dc09-2241 Komiya, 2008, Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension, Int Heart J, 49, 681, 10.1536/ihj.49.681 Hartog, 2010, Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction, Eur J Heart Fail, 12, 397, 10.1093/eurjhf/hfq001 Mosser, 1987, Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts, J Exp Med, 165, 140, 10.1084/jem.165.1.140 Munch, 1998, Alzheimer's disease—synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts, J Neural Transm, 105, 439, 10.1007/s007020050069 McNulty, 2007, Advanced glycation end-products and arterial stiffness in hypertension, Am J Hypertens, 20, 242, 10.1016/j.amjhyper.2006.08.009 Mitsuhashi, 1997, Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix, J Clin Invest, 100, 847, 10.1172/JCI119600 Snow, 2010, A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease, Mov Disord, 25, 1670, 10.1002/mds.23148